| Original language | English |
|---|---|
| Pages (from-to) | 1076-1088 |
| Number of pages | 13 |
| Journal | The Lancet Oncology |
| Volume | 18 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2017 |
Cite this
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. / Chiappella, A.; Martelli, M.; Angelucci, E.; Brusamolino, E.; Evangelista, A.; Carella, A.M.; Stelitano, C.; Rossi, G.; Balzarotti, M.; Merli, F.; Gaidano, G.; Pavone, V.; Rigacci, L.; Zaja, F.; D'Arco, A.; Cascavilla, N.; Russo, E.; Castellino, A.; Gotti, M.; Congiu, A.G.; Cabras, M.G.; Tucci, A.; Agostinelli, C.; Ciccone, G.; Pileri, S.A.; Vitolo, U.
In: The Lancet Oncology, Vol. 18, No. 8, 2017, p. 1076-1088.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
AU - Chiappella, A.
AU - Martelli, M.
AU - Angelucci, E.
AU - Brusamolino, E.
AU - Evangelista, A.
AU - Carella, A.M.
AU - Stelitano, C.
AU - Rossi, G.
AU - Balzarotti, M.
AU - Merli, F.
AU - Gaidano, G.
AU - Pavone, V.
AU - Rigacci, L.
AU - Zaja, F.
AU - D'Arco, A.
AU - Cascavilla, N.
AU - Russo, E.
AU - Castellino, A.
AU - Gotti, M.
AU - Congiu, A.G.
AU - Cabras, M.G.
AU - Tucci, A.
AU - Agostinelli, C.
AU - Ciccone, G.
AU - Pileri, S.A.
AU - Vitolo, U.
N1 - Cited By :4 Export Date: 2 March 2018
PY - 2017
Y1 - 2017
U2 - 10.1016/S1470-2045(17)30444-8
DO - 10.1016/S1470-2045(17)30444-8
M3 - Article
VL - 18
SP - 1076
EP - 1088
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 8
ER -